Prof. Dr. med. Matthias Fischer - Curriculum Vitae

Education and professional career

since 2016: Professor for Experimental Pediatric Oncology, University of Cologne
2015 - 2016: Research period at the Max-Planck-Institute for Metabolism Research, Cologne (Laboratory Prof. Dr. J. Brüning)
since 2014: Deputy head of the Department of Pediatric Oncology, University Hospital of Cologne
since 2013: Professor for Pediatrics, University of Cologne
since 2009: Consultant pediatric oncologist, University Hospital of Cologne
2007: “Habilitation” for Pediatrics, Medical Faculty, University of Cologne
2006: Board examination pediatrics
2005 - 2009: Resident physician, Department of Pediatric Oncology, University Hospital of Cologne
since 2001: Research group leader, Department of Pediatric Oncology, University of Cologne
1999 - 2005: M.D. thesis (Dr. med.), University of Cologne (Laboratory Prof. Dr. K. Rajewsky, Institute for Genetics)
1999: Medical state examination, University of Cologne

Awards, distinctions and professional activities

since 2017: Steering committee member of the Phase I/II pediatric oncology clinical trial consortium Rhine/Ruhr
since 2017: Board Director of the Massive Analysis and Quality Control (MAQC) society (former Microarray Quality Control consortium)
2016: Gerhard-Domagk Award for cancer research
since 2015: Board member of the Center for Integrated Oncology (CIO) Köln-Bonn
since 2014: Elected member of the Advances in Neuroblastoma Research Association (ANRA) Advisory Board Europe/Russia
since 2014: Member of the Individualized Therapy for Relapsed Malignancies in Childhood (INFORM) Committee
since 2011: Member of the International Neuroblastoma Risk Group (INRG) and International Neuroblastoma Response Criteria (INPC) consortia
since 2010: Member of the German Neuroblastoma Trial Committee

Selected publications

Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, Krämer A, Roncaioli JL, Sand F, Heuckmann J, Ikram F, Schmidt R, Ackermann S, Engesser A, Kahlert Y, Vogel W, Altmüller J, Nürnberg P, Thierry-Mieg J, Thierry-Mieg D, Mariappan A, Heynck S, Mariotti E, Henrich KO, Glöckner C, Bosco G, Leuschner I, Schweiger MR, Savelyeva L, Watkins SC, Shao C, Bell E, Höfer T, Achter V, Lang U, Theissen J, Volland R, Saadati M, Eggert A, de Wilde B, Berthold F, Peng Z, Zhao C, Shi L, Ortmann M, Büttner R, Perner S, Hero B, Schramm A, Schulte JH, Herrmann C, O’Sullivan RJ, Westermann F, Thomas RK, Fischer M. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature, 2015, 526: 700-704.

Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, Engesser A, Kahlert Y, Theissen J, Hero B, Roels F, Altmüller J, Nürnberg P, Astrahantseff K, Gloeckner C, De Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M, Speleman F, Schmezer P, Westermann F, Rahmann S*, Fischer M*, Eggert A*, Schulte JH*. Mutational dynamics between primary and relapse neuroblastomas. Nat Genet, 2015, 47(8): 872-877; *equal contribution.

Zhang W, Yu Y, Hertwig F, Thierry-Mieg J, Zhang W, Thierry-Mieg D, Wang J, Furlanello C, Devanarayan V, Cheng J, Deng Y, Hero B, Hong H, Jia M, Li L, Lin SM, Nikolsky Y, Oberthuer A, Qing T, Su Z, Volland R, Wang C, Wang MD, Ai J, Albanese D, Asgharzadeh S, Avigad S, Bao W, Bessarabova M, Brilliant MH, Brors B, Chierici M, Chu TM, Zhang J, Grundy RG, He MM, Hebbring S, Kaufman HL, Lababidi S, Lancashire LJ, Li Y, Lu XX, Luo H, Ma X, Ning B, Noguera R, Peifer M, Phan JH, Roels F, Rosswog C, Shao S, Shen J, Theissen J, Tonini GP, Vandesompele J, Wu PY, Xiao W, Xu J, Xu W, Xuan J, Yang Y, Ye Z, Dong Z, Zhang KK, Yin Y, Zhao C, Zheng Y, Wolfinger RD, Shi T, Malkas LH, Berthold F, Wang J, Tong W, Shi L, Peng Z, Fischer M. Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. Genome Biol, 2015, 16(1): 133.

Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger R, Ohira M, Nakagawara M, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, Brors B, Fischer M. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers. Clin Cancer Res, 2015, 21(8): 1904-1915.

Walz S, Lorenzin F, Morton J, Wiese KE, von Eyss B, Herold S, Rycak L, Dumay-Odelot H, Karim S, Bartkuhn M, Roels F, Wuestefeld T, Fischer M, Teichmann M, Zender L, Wei CL, Sansom O, Wolf E, Eilers M. Activation and repression by oncogenic Myc shape tumour-specific gene expression profiles. Nature, 2014, 511(7510): 483-487.

Su Z, Fang H, Hong H, Shi L, Zhang W, Zhang W, Zhang Y, Dong Z, Lancashire LJ, Bessarabova M, Yang X, Ning B, Gong B, Meehan J, Xu J, Ge W, Perkins R, Fischer M*, Tong W*. An investigation of biomarkers derived from legacy microarray data for their utility in the RNA-seq era. Genome Biol, 2014, 15(12): 523; *corresponding author.

Molenaar J, Domingo-Fernández R, Ebus M, Lindner S, Koster J, Drabek K, Mestdagh P, van Sluis P, Valentijn L, van Nes J, Broekmans M, Haneveld F, Volckmann R, Bray I, Heukamp L, Sprüssel A, Thor T, Kieckbusch K, Klein-Hitpass L, Fischer M, Vandesompele J, Schramm A, van Noesel M, Varesio L, Speleman F, Eggert A, Stallings R, Caron H, Versteeg R, Schulte JH. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet, 2012, 44(11): 1199-1206.

Ackermann S, Goeser F, Schulte JH, Schramm A, Ehemann V, Eggert A, Hero B, Berthold F, Fischer M. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma. Clin Cancer Res, 2011, 17(4): 731-741.

Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, Asgharzadeh S, Seeger R, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Vermeulen J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Weber A, Christiansen H, Grundy RG, Schardt K, Schwab M, Eils R, Warnat P, Kaderali L, Simon T, DeCarolis B, Theissen J, Westermann F, Brors B, Fischer M. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol, 2010, 28: 3506-3515.

Oberthür A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, König R, Haas S, Eils R, Schwab M, Brors B, Westermann F, Fischer M. Customized oligonucleotide microarray gene-expression based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol, 2006, 24: 5070-5078.